Artiva Biotherapeutics, Inc. Operating Lease Cost
Artiva Biotherapeutics, Inc. (ARTV) reported Operating Lease Cost of $843.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $843.00K, a 18.08% decline year-over-year.
- Artiva Biotherapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $843.00K, a 13.54% decline year-over-year.
- Artiva Biotherapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $961.00K, a 4.76% decline year-over-year.
- Artiva Biotherapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $1.01M, a 0.50% increase year-over-year.
- Artiva Biotherapeutics, Inc. operating lease, cost for fiscal 2025 was $4.01M, a 1.11% decline from fiscal 2024.
- Artiva Biotherapeutics, Inc. operating lease, cost for fiscal 2024 was $4.05M, a 1.48% decline from fiscal 2023.
- Artiva Biotherapeutics, Inc. operating lease, cost for fiscal 2023 was $4.11M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $843.00K 10-Q · filed 2026-08-06 | $1.69M 10-Q · filed 2026-08-06 | $2.65M derived: sum of 3 quarters · filed 2026-08-06 | $3.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $843.00K 10-Q · filed 2026-05-08 | $1.80M derived: sum of 2 quarters · filed 2026-05-08 | $2.81M derived: sum of 3 quarters · filed 2026-05-08 | $3.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $961.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.97M derived: sum of 2 quarters · filed 2026-03-10 | $3.00M derived: sum of 3 quarters · filed 2026-08-06 | $4.01M 10-K · filed 2026-03-10 |
| 2025-09-30 | $1.01M 10-Q · filed 2025-11-12 | $2.04M derived: sum of 2 quarters · filed 2026-08-06 | $3.05M 10-Q · filed 2025-11-12 | $4.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.03M 10-Q · filed 2026-08-06 | $2.04M 10-Q · filed 2026-08-06 | $3.01M derived: sum of 3 quarters · filed 2026-08-06 | $4.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $975.00K 10-Q · filed 2026-05-08 | $1.98M derived: sum of 2 quarters · filed 2026-05-08 | $2.99M derived: sum of 3 quarters · filed 2026-05-08 | $4.01M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.01M derived: sum of 2 quarters · filed 2026-03-10 | $3.03M derived: sum of 3 quarters · filed 2026-03-10 | $4.05M 10-K · filed 2026-03-10 |
| 2024-09-30 | $1.00M 10-Q · filed 2025-11-12 | $2.02M derived: sum of 2 quarters · filed 2025-11-12 | $3.04M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $1.02M 10-Q · filed 2025-08-06 | $2.04M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $1.02M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $4.11M 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |